Introduction of Indatuximab

Indatuximab is a humanized anti-CD138 monoclonal antibody (mAb) developed by Biotest Pharma. Indatuximab is directed against the cell surface antigen CD138, which is highly expressed in multiple myeloma and other hematologic malignancies. Current research on indatuximab is focused on the development of ADC drugs. Indatuximab ravtansine (BT-062) specifically binds to CD138 and selectively delivers its cytotoxic payload, DM4, directly to the cancer cells, thereby minimizing the impact on healthy tissues. Clinical trials have shown promising results for indatuximab ravtansine in patients with relapsed or refractory multiple myeloma, demonstrating significant antitumor activity and manageable safety profiles. As a result, this ADC is being closely watched as a potential new option for patients with difficult-to-treat cancers.

Mechanism of Action of Indatuximab

Syndecan-1 (CD138) is a cell-surface heparan sulfate overexpressed in multiple myeloma cells and several carcinomas. Indatuximab is a monoclonal antibody targeting CD138 for treating oncology, skin and musculoskeletal disorders, and genitourinary disorders. Clinical trials are being studied for investigational indications including bladder cancer and breast cancer, except multiple myeloma. Specific drugs targeting CD138 are currently being assessed, in which indatuximab ravtansine (BT-062) is an ADC drug that operates through a sophisticated mechanism of action that leverages the specificity of monoclonal antibodies and the potency of cytotoxic drugs. The drug comprises a monoclonal antibody targeting the CD138 antigen, which is predominantly expressed on the surface of multiple myeloma cells and other hematologic malignancies. Upon administration, indatuximab ravtansine binds specifically to CD138 on the surface of the cancer cells. This binding triggers the internalization of ADCs. When internalization comes, ADC cleaves, releasing DM4 into the intracellular environment. DM4 as a potent microtubule-disrupting agent then exerts its cytotoxic effects by binding to tubulin and inhibiting microtubule dynamics. This disruption leads to cell cycle arrest and subsequent apoptosis, effectively causing the death of cancer cells.

Progresses in Research and Development of ADCs

BT062 has demonstrated an excellent safety profile across clinical studies. Fatigue, thrombocytopenia, and peripheral neuropathy are common side effects that may usually be controlled with dosage modifications. Clinical trial effectiveness statistics have shown promise in improving survival rates and tumor response rates in patients with relapsed or refractory multiple myeloma. A potential therapy option for people with multiple myeloma is indatuximab ravtansine, especially for those who have relapsed or are not responding to current therapies. Potential areas of future research might include:

1. Combination Therapies: Exploring combinations with other novel agents to enhance efficacy and overcome resistance mechanisms.
2. Biomarker Studies: Identifying biomarkers to predict response and guide patient selection.
3. Solid Tumors: Investigating the potential of indatuximab ravtansine in solid tumors expressing CD138.

Know more about indatuximab ravtansine.

For research use only. Not intended for any clinical use.